CalciMedica reports positive Phase 2b CARPO data: 100% reduction in severe respiratory failure with high-dose Auxora

CalciMedica, Inc.

100% relative risk reduction (p=0.0027) in new-onset severe respiratory failure for combined high/medium dose vs low dose/placebo.
Stratified win ratio of 1.640 (p=0.0372) for high dose (2.0 mg/kg) Auxora vs placebo across key endpoints.
No drug-related serious adverse events or deaths at high dose; trend of decreasing TESAE rates with higher dose.
Planning end-of-Phase 2 meeting with FDA to design Phase 3 trial of Auxora in acute pancreatitis with SIRS.
Median time to medically indicated discharge reduced by 15 hours for high dose vs placebo (89 vs 104 hours).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.